Market news

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]

The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.

Vertex Pharmaceuticals (VRTX) has completed its acquisition of Crinetics Pharmaceuticals (CRNX), Ver

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals , Inc. (NasdaqGS: CRNX) to...

Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired revenue of US$25.12 million with a net loss of US$120.86 million and a basic loss per share of US$1.14. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' share price has risen strongly over the past year, with a 30 day share price return of 98.34% and a 1 year total shareholder return of 186.46%, reflecting rising expectations after the Vertex acquisition...

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor

There are other reasons to pay attention to Viking Therapeutics.

There are other reasons to pay attention to Viking Therapeutics.

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]

Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Motley Fool Press Release.

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week

Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector. Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target. Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019. Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital...

Detailed price information for Bioventus Inc Cl A (BVS-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]

The acquisition is expected to close in the third quarter of 2026.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash). Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion. Read Also: Ver

These are the stocks posting the largest moves in early trading.

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.